Autolus Therapeutics (AUTL) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed Autolus Therapeutics (AUTL) over the past year, gaining 41.4% versus a gain of 0.6%. Over five years, OVID leads with a -31.7% price change compared with -71.2% for AUTL. Autolus Therapeutics is the larger company by market cap ($481.8 million vs $480.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | OVID |
|---|---|---|
| Share price | $1.81 | $2.46 |
| Market cap | $481.75M | $480.43M |
| 1-day change | +2.26% | +5.13% |
| YTD return | -11.06% | +50.92% |
| 1-year return | +0.57% | +41.38% |
| 5-year return | -71.17% | -31.67% |
| EPS (TTM) | $-1.09 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.58 | $3.11 |
| 52-week low | $1.18 | $1.18 |
| Distance from 52-week high | -29.84% | -20.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +382.32% | +144.72% |
| Average volume | 2.10M | 1.57M |
| Shares outstanding | 266.16M | 195.30M |
| Employees | 752 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed AUTL by 40.8 percentage points over the past year.
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
AUTL vs OVID FAQ
Which is bigger, Autolus Therapeutics or Ovid Therapeutics?
Autolus Therapeutics (AUTL) is larger, with a market capitalization of $481.75M compared with $480.43M for Ovid Therapeutics (OVID).
Which stock has performed better over the past year, AUTL or OVID?
OVID returned +41.38% over the past 12 months, compared with +0.57% for AUTL (price return, excluding dividends). Past performance does not predict future results.
Are Autolus Therapeutics and Ovid Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Autolus Therapeutics and Biotechnology: Pharmaceutical Preparations for Ovid Therapeutics.